MedWatch

Demant won major market shares at VA in May

In May, the hearing aid company company Demant advanced in the public US sales channel Veterans Affairs, while GN Hearing retreated for the sixth month in a row.

Demant CEO Søren Nielsen | Photo: Kenneth Lysbjerg Koustrup/ERH

Demant won major market shares in hearing aids in the public US sales channel Veterans Affairs (VA) in May, as the firm's top product Oticon More was included in the VA contract as of May. GN Hearing only retreated a little, according to the most recent monthly report from VA.

For GN Hearing, this is the sixth month in a row that the firm retreated, as its market share dropped to 8.87 percent in May from 10.27 percent in April.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs